Destrometorfano Bromidrato Farmakopea (Dextromethorphan Hydrobromide)

Destrometorfano Bromidrato Farmakopea is indicated for the temporary relief of non‑productive cough associated with minor throat and bronchial irritation.

• Suppresses cough caused by common cold.
• Alleviates dry cough during seasonal allergies.
• Used as an adjunct for cough related to mild upper respiratory infections.
• Provides symptomatic relief when a cough interferes with sleep or daily activities.
• May be recommended for cough associated with irritant exposure (e.g., smoke, dust).

The safety profile of dextromethorphan hydrobromide includes both common and less frequent adverse effects that may be observed with oral use.

Common

• Drowsiness or mild sedation.
• Nausea or upset stomach.
• Dizziness or light‑headed feeling.
• Dry mouth.

Serious

• Severe allergic reaction (rash, itching, swelling, difficulty breathing).
• Hallucinations or altered mental status.
• Rapid heart rate (tachycardia) or irregular heartbeat.
• Persistent vomiting.

Before using Destrometorfano Bromidrato Farmakopea, certain precautions should be considered to ensure safe and appropriate use.

• Avoid use in individuals with known hypersensitivity to dextromethorphan or any formulation components.
• Use cautiously in patients taking monoamine oxidase inhibitors (MAOIs) or within 14 days after discontinuation.
• Do not exceed the recommended dose, as high amounts can cause central nervous system effects.
• Pregnant or breastfeeding women should consult a healthcare professional before use.
• Individuals with liver disease may require dose adjustment or medical advice.
• Children under the age recommended for OTC cough suppressants should not be given this product.

Dextromethorphan hydrobromide can interact with several medications; awareness of these interactions helps prevent adverse outcomes.

Avoid

• Monoamine oxidase inhibitors (MAOIs) and related drugs (e.g., phenelzine, tranylcypromine).
• Selective serotonin reuptake inhibitors (SSRIs) or other serotonergic agents (risk of serotonin syndrome).
• Certain anticholinergic medications that may increase central side effects.

Use with caution

• Alcohol or other central nervous system depressants.
• Medications that affect CYP2D6 metabolism (e.g., quinidine, fluoxetine) which can raise dextromethorphan levels.
• Opioid analgesics, as combined use may enhance respiratory depression.